View Lipid Standardization Presentation
Lipid Standardization Program
The Centers for Disease Control and Prevention, Lipid Standardization Program (LSP) has been operational for over 50 years. The LSP standardizes lipid testing for research laboratories, but not for clinical laboratories that serve health care organizations and patient care. To prevent over- or under-diagnosis of chronic diseases, this program needs to include clinical testing laboratories disease biomarkers other than lipids.
Lack of standardization of clinical laboratory tests can result in unreliable blood test results, resulting in missed diagnoses (false negative test results) or over diagnoses (false positives). Each of these problems comes with both economic and patient health costs. Expansion of the CDC standardization program, to assure accurate and reliable test results and to include new and emerging markers of cardiovascular and other chronic diseases is needed to assure that clinical trials are conducted with the highest quality data and that patients receive accurate reliable diagnoses and the highest possible quality of care.
The National Association of Chronic Disease Directors (NACDD) and the Division of Laboratory Sciences at the Centers for Disease Control and Prevention are collaborating to resolve these problems. With technical guidance from experts who comprise the Cardiovascular Biomarker Standardization Steering Committee, the Cardiovascular Biomarker Standardization Program is working to advocate for funds to implement the tools needed for standardization, assuring the highest standards of laboratory testing in clinical and research laboratories across the United States.
The Cardiovascular Biomarker Standardization Program will:
- Continue standardizing laboratory tests that have already had accepted standards.
- Evaluate the existing standardization data on new biomarkers.
- Select new biomarkers for inclusion in the program.
- Develop reference systems including:
- reference materials and
- reference methods.
- Standardize new biomarker measurements including:
- Standardization of research laboratories and
- Standardization of manufacturers and routine laboratories,
- Improve communication to current and potential program users.
- Assist in translating laboratory-based research findings into public health strategies